Clinical Trial Update: Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial examining the combination of sacituzumab tirumotecan and toripalimab as first-line therapy for recurrent or metastatic head and neck squamous cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Sacituzumab Tirumotecan (Sacituzumab govitecan)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING